Genomadix Inc. Announces Know-How License Agreement with Mayo Clinic
OTTAWA, ON, Aug. 29, 2022 /CNW/ – Genomadix today announced it has entered into a know-how license agreement and stock purchase agreement with Mayo Clinic to advance its point of care molecular analyzer technology. The Genomadix CubeTM uses polymerase chain reaction (PCR) technology in a small and portable footprint to generate timely (one hour), accurate test results, expanding the reach beyond centralized labs.
The Genomadix CubeTM testing system already delivers environmental testing for potentially deadly Legionella bacteria in water sources such as building cooling towers and CYP2C19 genotype guided antiplatelet therapy in Europe with efforts underway for US authorization. Additionally, a COVID-19 product has been developed with introduction slated (pending authorization) for later in 2022.
“We are extremely proud to be collaborating with Mayo Clinic to progress our technology and mission to make highly accurate molecular testing available for the benefit of patients. This collaboration seeks to seed new product developments with focused expertise provided by Mayo Clinic experts” commented Steve Edgett, Genomadix’s CEO
Mayo Clinic has a financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education, and research.
Genomadix Inc. is a pioneer in real-time RT-PCR point of use technology, dedicated to the highest level of customer satisfaction, quality, and support, maintaining ISO 13485 medical device development and manufacturing standards certification. Based in Ottawa, Canada, the Genomadix CubeTM automates complex and tedious manual procedures, advancing sample to result DNA/RNA testing in clinical, environmental, infectious disease, and precision medicine. For more information, visit www.genomadix.com.
For further information: email@example.com
GENOMADIX ANNOUNCES FDA CLEARANCE TO MARKET THE GENOMADIX CUBE CYP2C19 SYSTEM
(OTTAWA, March 22, 2023) Genomadix , based in Ottawa, Canada, announced today the US Food and Drug Administration (FDA) granted 510(k) clearance permitting marketing of its “Genomadix CubeTM CYP2C19 System” …
Read GENOMADIX ANNOUNCES FDA CLEARANCE TO MARKET THE GENOMADIX CUBE CYP2C19 SYSTEM
GENOMADIX ANNOUNCES SECURING TWO YEARS OF FUNDING
GENOMADIX ANNOUNCES SECURING TWO YEARS OF FUNDING Diagnostic Provider Poised for Significant Growth Upon Market Authorization (OTTAWA, July 18, 2022) Genomadix , based in Ottawa, Canada, today announced that a …
Read GENOMADIX ANNOUNCES SECURING TWO YEARS OF FUNDING
Which Test Are You Looking For?